Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 6/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.49 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.47 |
| ▸ | CALCR | P30988 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talfirastide SCHEMBL15926158 | 0.97 | AGTR1 (0.59) | AGTR2AGTR1MC4RC5AR1NTSR1 | |
| SCHEMBL22912577 | 0.92 | AGTR2 (0.53) | AGTR2AGTR1MC4RC5AR1NTSR1 | |
| SCHEMBL29602954 | 0.92 | C5AR1 (0.55) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| SCHEMBL29972916 | 0.92 | AGTR1 (0.62) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| SCHEMBL9510693 | 0.92 | AGTR1 (0.60) | AGTR2AGTR1MC4RC5AR1NTSR1 | |
| SCHEMBL15928128 | 0.91 | AGTR2 (0.59) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| SCHEMBL30901127 | 0.91 | C5AR1 (0.52) | AGTR2AGTR1MC4RC5AR1NTSR1 | |
| Angiotensin-Ii SCHEMBL29973063 | 0.91 | AGTR2 (0.62) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| SCHEMBL7052378 | 0.91 | AGTR2 (0.65) | AGTR2AGTR1C5AR1NTSR1NTSR2 | |
| SCHEMBL29701256 | 0.90 | AGTR2 (0.65) | AGTR2AGTR1C5AR1NTSR1NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248708-A1 | Methods for Treating Systemic Lupus Erythematosus | UNIVERSITY OF SOUTHERN CALIFORNIA | 2023-08-10 | — | — | US | claimed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4284779-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230248708-A1 | Methods for Treating Systemic Lupus Erythematosus | UNIVERSITY OF SOUTHERN CALIFORNIA | 2023-08-10 | — | — | US | disclosed |
| US-11446285-B2 | Methods for treating systemic lupus erythematosus | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022165189-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | AGTR2 337/4885AGTR1 242/4885MC4R 104/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | AGTR2 337/4885AGTR1 242/4885MC4R 104/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | AGTR2 1203/4885AGTR1 1006/4885MC4R 398/4885 |
| US-11446285-B2 | Methods for treating systemic lupus erythematosus | SSB, SERPINA6, SERPINC1 | AGTR2 1544/4885AGTR1 1310/4885MC4R 1884/4885 |
| US-20230248708-A1 | Methods for Treating Systemic Lupus Erythematosus | SSB, SERPINA6, SERPINC1 | AGTR2 1649/4885AGTR1 1199/4885MC4R 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.